EnsoData is a healthcare technology startup that leverages artificial intelligence to enhance the diagnosis and treatment of sleep disorders. Its software employs advanced machine learning algorithms to analyze sleep data, enabling clinicians to efficiently score and diagnose conditions such as sleep apnea. By integrating best practices in scoring with innovative algorithms, EnsoData's platform automates the interpretation of complex sleep study data, significantly reducing review times for neurology labs. This efficiency not only streamlines the scoring process but also enhances patient outcomes and increases revenue for healthcare providers.
EnsoData is a healthcare technology startup that leverages artificial intelligence to enhance the diagnosis and treatment of sleep disorders. Its software employs advanced machine learning algorithms to analyze sleep data, enabling clinicians to efficiently score and diagnose conditions such as sleep apnea. By integrating best practices in scoring with innovative algorithms, EnsoData's platform automates the interpretation of complex sleep study data, significantly reducing review times for neurology labs. This efficiency not only streamlines the scoring process but also enhances patient outcomes and increases revenue for healthcare providers.
Invenra Inc. is a biopharmaceutical company specializing in the discovery of biologics, particularly antibodies and their derivatives. Founded in 2011 and located in Madison, Wisconsin, Invenra utilizes a proprietary technology that integrates cell-free expression of full-length antibodies with extreme miniaturization. This innovative approach allows for the screening of a vast number of full-length antibodies in phenotypic assays, facilitating the identification of next-generation biologics. The company boasts a strong scientific foundation and a team of experts with extensive knowledge in genomics, biochemistry, and bioengineering, blending advanced basic research with practical commercial applications.
HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, established in 2013. It specializes in providing innovative search, analytics, and imaging solutions primarily for cancer care providers. The company's smart imaging technology supports clinical decision-making by offering real-time, evidence-based insights that enhance diagnostic accuracy and foster collaboration among healthcare professionals. HealthMyne's platform includes features such as automatic tumor staging, dose overlays, specialized reporting, and management of incidental findings, all aimed at improving patient care and optimizing the efficiency of clinical workflows. By integrating electronic health record capabilities with advanced imaging solutions, HealthMyne seeks to reduce care delivery costs while ensuring that clinicians have access to relevant patient information for informed treatment decisions.
HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, established in 2013. It specializes in providing innovative search, analytics, and imaging solutions primarily for cancer care providers. The company's smart imaging technology supports clinical decision-making by offering real-time, evidence-based insights that enhance diagnostic accuracy and foster collaboration among healthcare professionals. HealthMyne's platform includes features such as automatic tumor staging, dose overlays, specialized reporting, and management of incidental findings, all aimed at improving patient care and optimizing the efficiency of clinical workflows. By integrating electronic health record capabilities with advanced imaging solutions, HealthMyne seeks to reduce care delivery costs while ensuring that clinicians have access to relevant patient information for informed treatment decisions.
FluGen, Inc. is a biopharmaceutical company focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007 and based in Madison, Wisconsin, FluGen offers RedeeFlu, a nasal spray vaccine designed to protect against influenza, along with a vaccine-loaded intradermal microneedle delivery device. The company aims to address both seasonal and pandemic influenza on a global scale.
Elucent Medical LLC is focused on enhancing breast cancer treatment through innovative technology. Founded in 2014 and headquartered in Brookfield, Wisconsin, the company has developed a wireless marker tag and detection system that assists surgeons in locating breast abnormalities during surgical excision. This system aims to eliminate the need for metal clips, thereby simplifying the detection process and improving surgical outcomes. By providing tools that allow for the preservation of healthy tissue while effectively removing cancerous areas, Elucent Medical strives to make breast cancer procedures more accessible and affordable for both healthcare providers and patients.
TAI Diagnostics, Inc. is a biotechnology company based in Wauwatosa, Wisconsin, specializing in non-invasive diagnostic tests for monitoring the health of transplanted organs in patients who have received solid organ transplants. Founded in 2013, the company focuses on utilizing cell-free DNA technology to enhance transplant surveillance, aiming to improve patient outcomes through highly sensitive diagnostic solutions. TAI Diagnostics is situated in the Milwaukee County Research Park, close to notable medical research institutions, which supports its mission to advance the field of organ transplant monitoring.
Madison Vaccines, Inc. is a biopharmaceutical company based in Madison, Wisconsin, focused on developing therapeutic plasmid DNA vaccines for prostate cancer and its associated bone metastases. Founded by Douglas McNeel, M.D., Ph.D., and Richard Lesniewski, Ph.D., the company is working on two primary vaccines: pTVG-HP and pTVG-AR. The lead vaccine, pTVG-HP, is administered via intradermal injection and targets prostatic acid phosphatase (PAP), with ongoing Phase 2 clinical trials for men at high risk of developing bone metastases following prostate cancer treatment. Initial trials have shown promising biological and biochemical activity. The second vaccine, pTVG-AR, aims to target the androgen receptor, a key driver of prostate cancer growth, and is expected to enter clinical trials soon. Additionally, Madison Vaccines is developing a companion diagnostic test based on a novel blood signature identified by the McNeel lab, which could help predict patient responses to these vaccines.
HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, established in 2013. It specializes in providing innovative search, analytics, and imaging solutions primarily for cancer care providers. The company's smart imaging technology supports clinical decision-making by offering real-time, evidence-based insights that enhance diagnostic accuracy and foster collaboration among healthcare professionals. HealthMyne's platform includes features such as automatic tumor staging, dose overlays, specialized reporting, and management of incidental findings, all aimed at improving patient care and optimizing the efficiency of clinical workflows. By integrating electronic health record capabilities with advanced imaging solutions, HealthMyne seeks to reduce care delivery costs while ensuring that clinicians have access to relevant patient information for informed treatment decisions.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
FluGen, Inc. is a biopharmaceutical company focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007 and based in Madison, Wisconsin, FluGen offers RedeeFlu, a nasal spray vaccine designed to protect against influenza, along with a vaccine-loaded intradermal microneedle delivery device. The company aims to address both seasonal and pandemic influenza on a global scale.
TAI Diagnostics, Inc. is a biotechnology company based in Wauwatosa, Wisconsin, specializing in non-invasive diagnostic tests for monitoring the health of transplanted organs in patients who have received solid organ transplants. Founded in 2013, the company focuses on utilizing cell-free DNA technology to enhance transplant surveillance, aiming to improve patient outcomes through highly sensitive diagnostic solutions. TAI Diagnostics is situated in the Milwaukee County Research Park, close to notable medical research institutions, which supports its mission to advance the field of organ transplant monitoring.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
FluGen, Inc. is a biopharmaceutical company focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007 and based in Madison, Wisconsin, FluGen offers RedeeFlu, a nasal spray vaccine designed to protect against influenza, along with a vaccine-loaded intradermal microneedle delivery device. The company aims to address both seasonal and pandemic influenza on a global scale.
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.
HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, established in 2013. It specializes in providing innovative search, analytics, and imaging solutions primarily for cancer care providers. The company's smart imaging technology supports clinical decision-making by offering real-time, evidence-based insights that enhance diagnostic accuracy and foster collaboration among healthcare professionals. HealthMyne's platform includes features such as automatic tumor staging, dose overlays, specialized reporting, and management of incidental findings, all aimed at improving patient care and optimizing the efficiency of clinical workflows. By integrating electronic health record capabilities with advanced imaging solutions, HealthMyne seeks to reduce care delivery costs while ensuring that clinicians have access to relevant patient information for informed treatment decisions.
Madison Vaccines, Inc. is a biopharmaceutical company based in Madison, Wisconsin, focused on developing therapeutic plasmid DNA vaccines for prostate cancer and its associated bone metastases. Founded by Douglas McNeel, M.D., Ph.D., and Richard Lesniewski, Ph.D., the company is working on two primary vaccines: pTVG-HP and pTVG-AR. The lead vaccine, pTVG-HP, is administered via intradermal injection and targets prostatic acid phosphatase (PAP), with ongoing Phase 2 clinical trials for men at high risk of developing bone metastases following prostate cancer treatment. Initial trials have shown promising biological and biochemical activity. The second vaccine, pTVG-AR, aims to target the androgen receptor, a key driver of prostate cancer growth, and is expected to enter clinical trials soon. Additionally, Madison Vaccines is developing a companion diagnostic test based on a novel blood signature identified by the McNeel lab, which could help predict patient responses to these vaccines.
Thalchemy Corp. develops neurally-inspired algorithms and accelerators aimed at continuous sensory processing in smartphones and other battery-operated devices. By mimicking the functionality of the mammalian thalamus, the company's technology allows for the routing, filtering, and preprocessing of sensory data, which enhances the detection of complex gestures and hot words across multiple modalities. This innovative approach significantly extends battery life for devices such as smartphones and wearables, while providing optimized voice and gesture control. Thalchemy's solutions also support the creation of always-on applications, simplifying development through an automated, user-friendly interface. Additionally, the technology can monitor environmental conditions, enabling applications that alert users or caregivers in emergency situations, such as falls or irregular heartbeats. Founded in 2012 and based in Madison, Wisconsin, Thalchemy aims to transform user interfaces and experiences across a variety of sensing platforms.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
Thalchemy Corp. develops neurally-inspired algorithms and accelerators aimed at continuous sensory processing in smartphones and other battery-operated devices. By mimicking the functionality of the mammalian thalamus, the company's technology allows for the routing, filtering, and preprocessing of sensory data, which enhances the detection of complex gestures and hot words across multiple modalities. This innovative approach significantly extends battery life for devices such as smartphones and wearables, while providing optimized voice and gesture control. Thalchemy's solutions also support the creation of always-on applications, simplifying development through an automated, user-friendly interface. Additionally, the technology can monitor environmental conditions, enabling applications that alert users or caregivers in emergency situations, such as falls or irregular heartbeats. Founded in 2012 and based in Madison, Wisconsin, Thalchemy aims to transform user interfaces and experiences across a variety of sensing platforms.
Madison Vaccines, Inc. is a biopharmaceutical company based in Madison, Wisconsin, focused on developing therapeutic plasmid DNA vaccines for prostate cancer and its associated bone metastases. Founded by Douglas McNeel, M.D., Ph.D., and Richard Lesniewski, Ph.D., the company is working on two primary vaccines: pTVG-HP and pTVG-AR. The lead vaccine, pTVG-HP, is administered via intradermal injection and targets prostatic acid phosphatase (PAP), with ongoing Phase 2 clinical trials for men at high risk of developing bone metastases following prostate cancer treatment. Initial trials have shown promising biological and biochemical activity. The second vaccine, pTVG-AR, aims to target the androgen receptor, a key driver of prostate cancer growth, and is expected to enter clinical trials soon. Additionally, Madison Vaccines is developing a companion diagnostic test based on a novel blood signature identified by the McNeel lab, which could help predict patient responses to these vaccines.
Cellectar Biosciences is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of cancer therapies. Based in Florham Park, New Jersey, the company focuses on its proprietary phospholipid drug conjugate (PDC) platform, which aims to enhance the targeted delivery of cancer treatments while minimizing side effects. Its lead product candidate, CLR 131, is currently undergoing Phase II clinical trials for relapsed or refractory multiple myeloma and various B-cell malignancies. In addition, Cellectar is developing CLR 1900, a chemotherapeutic program aimed at solid tumors. The company also collaborates with several partners to advance various PDC programs, including those targeting specific cancer types. Originally established in 2002 as Novelos Therapeutics, Inc., Cellectar Biosciences has evolved through various name changes and strategic initiatives to focus on innovative cancer treatment solutions.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
Tissue Regeneration Systems Inc. is a start-up medical device company focused on skeletal reconstruction and bone regeneration technologies, licensed from the Universities of Michigan and Wisconsin. Established in 2005 and headquartered in Plymouth, Michigan, with a research facility in Ann Arbor and an additional office in Kirkland, Washington, the company targets applications in craniomaxillofacial surgery, orthopedic surgery, spine fusion surgery, and bone growth factor delivery. Its technology has undergone extensive evaluation in large animal studies, yielding promising long-term results. The company has developed initial product offerings, completed necessary bench and animal testing, and submitted its first regulatory filings to the FDA. Successful approval of these submissions will facilitate the commercialization of its products in the United States, with expectations to generate significant revenue within the next two to three years.
Nextt, Inc. is a technology company based in Madison, Wisconsin, that specializes in developing web and mobile application software. The company's primary offering is a private networking platform designed to help close friends connect and organize social activities more effectively. By providing tools for sharing ideas and coordinating plans, Nextt simplifies the social planning process, allowing users to manage details such as participants, activities, timing, and locations in a secure environment. This approach encourages users to prioritize quality time with friends and fosters offline interactions.
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.
Mithridion, Inc. is a biopharmaceutical company based in Madison, Wisconsin, focused on discovering and developing small molecule drugs to address unmet medical needs, particularly in the area of central nervous system disorders. The company targets serious chronic neurodegenerative diseases, including orphan diseases and schizophrenia. Its drug portfolio includes MCD-386CR, aimed at treating cognitive impairments associated with Progressive Supranuclear Palsy and other neurodegenerative conditions; MCD-386/glycopyrrolate, designed as a preventative therapy for genetically-defined presymptomatic mutation carriers of autosomal dominant Alzheimer’s disease; MI-08-016/035, which are candidates for common neurodegenerative diseases; and MI-10-022, targeting significant unmet needs in schizophrenia. Founded in 2004, Mithridion aims to provide innovative therapeutic solutions for complex neurological conditions.
ProCertus BioPharm, Inc., an oncology-based pharmaceutical company, develops therapeutics to protect cancer patients from the side effects of radiotherapy and chemotherapy in the United States. Its products include ProDermaCel that protects cancer patients from chemotherapy- and radiotherapy-induced alopecia; DermX, which prevents radiotherapy-induced dermatitis; and OralX that provides protection against chemotherapy- and radiotherapy- induced oral mucositis. ProCertus BioPharm, Inc. was founded in 1997 and is based in Madison, Wisconsin.
Mithridion, Inc. is a biopharmaceutical company based in Madison, Wisconsin, focused on discovering and developing small molecule drugs to address unmet medical needs, particularly in the area of central nervous system disorders. The company targets serious chronic neurodegenerative diseases, including orphan diseases and schizophrenia. Its drug portfolio includes MCD-386CR, aimed at treating cognitive impairments associated with Progressive Supranuclear Palsy and other neurodegenerative conditions; MCD-386/glycopyrrolate, designed as a preventative therapy for genetically-defined presymptomatic mutation carriers of autosomal dominant Alzheimer’s disease; MI-08-016/035, which are candidates for common neurodegenerative diseases; and MI-10-022, targeting significant unmet needs in schizophrenia. Founded in 2004, Mithridion aims to provide innovative therapeutic solutions for complex neurological conditions.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
Tissue Regeneration Systems Inc. is a start-up medical device company focused on skeletal reconstruction and bone regeneration technologies, licensed from the Universities of Michigan and Wisconsin. Established in 2005 and headquartered in Plymouth, Michigan, with a research facility in Ann Arbor and an additional office in Kirkland, Washington, the company targets applications in craniomaxillofacial surgery, orthopedic surgery, spine fusion surgery, and bone growth factor delivery. Its technology has undergone extensive evaluation in large animal studies, yielding promising long-term results. The company has developed initial product offerings, completed necessary bench and animal testing, and submitted its first regulatory filings to the FDA. Successful approval of these submissions will facilitate the commercialization of its products in the United States, with expectations to generate significant revenue within the next two to three years.
At Nerites, they combine world class technology with a management team that has a proven track record of bringing technical innovation to market. The company was founded in 2004 to commercialize a new generation of synthetic biomaterials that can enhance natural tissue repair, reduce complications from traditional devices, and degrade safely when they are no longer needed.
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.
Cellectar Biosciences is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of cancer therapies. Based in Florham Park, New Jersey, the company focuses on its proprietary phospholipid drug conjugate (PDC) platform, which aims to enhance the targeted delivery of cancer treatments while minimizing side effects. Its lead product candidate, CLR 131, is currently undergoing Phase II clinical trials for relapsed or refractory multiple myeloma and various B-cell malignancies. In addition, Cellectar is developing CLR 1900, a chemotherapeutic program aimed at solid tumors. The company also collaborates with several partners to advance various PDC programs, including those targeting specific cancer types. Originally established in 2002 as Novelos Therapeutics, Inc., Cellectar Biosciences has evolved through various name changes and strategic initiatives to focus on innovative cancer treatment solutions.
Deltanoid Pharmaceuticals is a biopharmaceutical company based in Madison, Wisconsin, focused on the research, development, and commercialization of therapies for various human diseases, including renal diseases, osteoporosis, and skin conditions. Founded in 1999, the company initially aimed to advance university inventions, particularly vitamin D analogs and other compounds licensed from the Wisconsin Alumni Research Foundation. Deltanoid's notable products include DP001, which targets secondary hyperparathyroidism in patients with chronic kidney disease undergoing hemodialysis, and DP006 for acne treatment. The company is dedicated to developing selected therapies through the early phases of drug development and actively seeks partnerships for later-stage development and commercialization. Currently, Deltanoid has a partnership with Novadiol, Inc. for the development of a vitamin D therapy.
Virent Energy Systems, Inc. is an energy technology company based in Madison, Wisconsin, specializing in the production of hydrocarbon chemicals and fuels from plant sugars. Utilizing its patented BioForming technology, Virent converts various bio-based feedstocks, such as beet sugar, sugar cane, corn starch, and cellulosic materials like bagasse and corn stover, into products that are chemically identical to petroleum-derived fuels and chemicals. The company’s offerings include gasoline, diesel, jet fuel, and bio-aromatic compounds used in a variety of applications, such as paints, textiles, and automotive products. Virent has established strategic partnerships with notable companies, including Royal Dutch Shell and The Coca-Cola Company, to further its mission of providing renewable alternatives to fossil fuels. Founded in 2002, Virent operates as a subsidiary of Marathon Petroleum Corporation.
ProCertus BioPharm, Inc., an oncology-based pharmaceutical company, develops therapeutics to protect cancer patients from the side effects of radiotherapy and chemotherapy in the United States. Its products include ProDermaCel that protects cancer patients from chemotherapy- and radiotherapy-induced alopecia; DermX, which prevents radiotherapy-induced dermatitis; and OralX that provides protection against chemotherapy- and radiotherapy- induced oral mucositis. ProCertus BioPharm, Inc. was founded in 1997 and is based in Madison, Wisconsin.
Mithridion, Inc. is a biopharmaceutical company based in Madison, Wisconsin, focused on discovering and developing small molecule drugs to address unmet medical needs, particularly in the area of central nervous system disorders. The company targets serious chronic neurodegenerative diseases, including orphan diseases and schizophrenia. Its drug portfolio includes MCD-386CR, aimed at treating cognitive impairments associated with Progressive Supranuclear Palsy and other neurodegenerative conditions; MCD-386/glycopyrrolate, designed as a preventative therapy for genetically-defined presymptomatic mutation carriers of autosomal dominant Alzheimer’s disease; MI-08-016/035, which are candidates for common neurodegenerative diseases; and MI-10-022, targeting significant unmet needs in schizophrenia. Founded in 2004, Mithridion aims to provide innovative therapeutic solutions for complex neurological conditions.
Virent Energy Systems, Inc. is an energy technology company based in Madison, Wisconsin, specializing in the production of hydrocarbon chemicals and fuels from plant sugars. Utilizing its patented BioForming technology, Virent converts various bio-based feedstocks, such as beet sugar, sugar cane, corn starch, and cellulosic materials like bagasse and corn stover, into products that are chemically identical to petroleum-derived fuels and chemicals. The company’s offerings include gasoline, diesel, jet fuel, and bio-aromatic compounds used in a variety of applications, such as paints, textiles, and automotive products. Virent has established strategic partnerships with notable companies, including Royal Dutch Shell and The Coca-Cola Company, to further its mission of providing renewable alternatives to fossil fuels. Founded in 2002, Virent operates as a subsidiary of Marathon Petroleum Corporation.
ZyStor Therapeutics, Inc. is a privately-held biotechnology company developing enzyme replacement therapies for the treatment of lysosomal storage diseases.
Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Corona Optical Systems is a high-technology company based in Lombard, Illinois, with additional facilities in Eau Claire, Wisconsin, and San Jose, California. Founded in February 2000, the company specializes in the development and manufacturing of optoelectronic components and subsystems designed for carrier-class equipment. Its primary focus includes creating parallel optical modules that are utilized in switching and routing technologies. As a privately held corporation, Corona has attracted venture capital funding to support its growth, including a significant institutional investment round in 2001 led by Intel Capital and involving several other prominent venture firms.
SoftSwitching Technologies offer the most affordable, effective and scalable power quality and monitoring solutions available on the market. A full array of scalable, battery-free DySC products. I-Sense intelligent sensors that pinpoint time and duration of voltage sags. And Grid Alert™ event notifications—the only global power reporting and notification network in the world.
Gala Biotech, a Catalent Pharma Solutions Company, was established in 1996 from technology developed at the University of Wisconsin. Located in Middleton, Wisconsin, this rapidly growing company (currently over 40 employees, including 16 PhD’s) has a wide range of capabilities in the fields of molecular biology, vector biology, cell line development, biopharmaceutical manufacturing, protein biochemistry, and quality systems. Gala’s core proprietary technology is GPEx® (Gene Product Expression), a gene insertion/expression technology that allows rapid creation of stable, high-expressing mammalian cell lines for a wide variety of gene products. "Gala" is Greek for milk, and the company's original mission was to produce pharmaceutical proteins in the milk of transgenic cows. The gene insertion technology that Gala developed to generate transgenic animals became the basis of Gala's Gene Product Expression or GPEx® technology for production of recombinant proteins in mammalian cell culture. The genomics revolution has led to the identification of thousands of new genes, and the race is now on to discover, characterize and stably express the protein products of these genes in order to develop new therapeutic proteins. Gala's GPEx® technology, when applied to mammalian cell culture, accelerates this process for its biopharmaceutical partners. Once new therapeutic proteins have been identified for clinical development, production support becomes a major challenge. Gala's mission is to meet this need, and the company has recently established a 43,000 square-foot facility in Middleton, Wisconsin devoted to GPEx®-based cell line development and cGMP-compliant protein production.
Alfalight specializes in the design and manufacture of high-power diode lasers tailored for industrial, defense, and telecommunications applications. The company utilizes advanced aluminum-free active region (ALFA) laser structures, which contribute to the production of laser diodes that are noted for their high reliability and efficiency. Alfalight's product range includes short-wave infrared, near-infrared, and visible lasers, alongside various laser and electro-optical systems. These innovations position Alfalight as a key player in meeting the demands of both security and telecommunication sectors.
TomoTherapy develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy:registered: platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its Hi·Art:registered: treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD:tm: treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile:tm: relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. As of February 2011, there are more than 350 TomoTherapy systems in use in 24 countries worldwide. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
Third Wave Technologies, Inc. is involved in the development and marketing of molecular diagnostic products that cater to a range of DNA and RNA analysis applications. The company provides innovative solutions for physicians and researchers focused on disease analysis and treatment. Its proprietary Invader chemistry is utilized across several segments, including women's health, infectious diseases, genetics, pharmacogenetics, and oncology. Third Wave offers in vitro diagnostic devices and analyte-specific reagents that enable laboratories to perform various assays, such as hepatitis C virus genotyping and testing for inherited disorders and genetic mutations. Additionally, the company develops products for research and agricultural biotechnology markets. Its clientele comprises clinical laboratories, pharmaceutical and biotechnology companies, academic institutions, and healthcare providers. Third Wave employs direct sales strategies and collaborative partnerships to market its products in the United States and Europe. Founded in 1993, Third Wave Technologies is headquartered in Madison, Wisconsin, and is currently a subsidiary of Hologic Inc.
Promega Corporation, founded in 1978 and based in Madison, Wisconsin, produces a diverse range of reagents and instrumentation for research, pharmaceutical, and diagnostics laboratories. The company offers over 2,000 products that support various applications, including cell biology, nucleic acid analysis, protein analysis, and molecular diagnostics. Its offerings encompass tools for drug discovery, clinical research, forensic analysis, and human identification. In addition to standard products, Promega provides custom manufacturing, assay development, and automation solutions to enhance efficiency and precision in laboratory procedures. The company distributes its products globally, catering to the needs of researchers and clinicians in multiple scientific fields.